After having dinner with CFO Nicky McGrane, Jefferies analyst Sean Dodge believes the current $860M 2019 Street revenue estimate for Evolent Health “is within reach.” This remains the primary focus of investors, Dodge tells investors in a research note. While admitting visibility isn’t 100% yet, the analyst reiterates a Buy rating on Evolent with a $30 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.